BR112018005741A2 - método de redirecionamento de células t para tratar infecção por hiv - Google Patents

método de redirecionamento de células t para tratar infecção por hiv

Info

Publication number
BR112018005741A2
BR112018005741A2 BR112018005741A BR112018005741A BR112018005741A2 BR 112018005741 A2 BR112018005741 A2 BR 112018005741A2 BR 112018005741 A BR112018005741 A BR 112018005741A BR 112018005741 A BR112018005741 A BR 112018005741A BR 112018005741 A2 BR112018005741 A2 BR 112018005741A2
Authority
BR
Brazil
Prior art keywords
hiv infection
treat hiv
redirection method
cell redirection
hiv
Prior art date
Application number
BR112018005741A
Other languages
English (en)
Inventor
S Payne Aimee
T Ellebrecht Christoph
L Riley James
C Milone Michael
Leibman Rachel
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of BR112018005741A2 publication Critical patent/BR112018005741A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a composições e métodos para o tratamento de um mamífero infectado com hiv usando um receptor quimérico cd4 ligado à membrana ou cars de scfvs específicos para hiv. um aspecto inclui uma célula t modificada e composições farmacêuticas compreendendo as células modificadas para terapia celular adoptiva e tratamento de uma doença ou condição associada com infecção por hiv.
BR112018005741A 2015-09-22 2016-09-22 método de redirecionamento de células t para tratar infecção por hiv BR112018005741A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562222132P 2015-09-22 2015-09-22
US201562253790P 2015-11-11 2015-11-11
PCT/US2016/053097 WO2017053556A1 (en) 2015-09-22 2016-09-22 Method of redirecting t cells to treat hiv infection

Publications (1)

Publication Number Publication Date
BR112018005741A2 true BR112018005741A2 (pt) 2018-10-09

Family

ID=58387210

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005741A BR112018005741A2 (pt) 2015-09-22 2016-09-22 método de redirecionamento de células t para tratar infecção por hiv

Country Status (15)

Country Link
US (2) US10738099B2 (pt)
EP (1) EP3353197A4 (pt)
JP (1) JP6991131B2 (pt)
KR (1) KR20180050413A (pt)
CN (1) CN108779161A (pt)
AU (1) AU2016326500A1 (pt)
BR (1) BR112018005741A2 (pt)
CA (1) CA2999496A1 (pt)
CL (1) CL2018000750A1 (pt)
EA (1) EA201890782A1 (pt)
IL (1) IL258191A (pt)
MA (1) MA42951A (pt)
MX (1) MX2018003463A (pt)
PH (1) PH12018500609A1 (pt)
WO (1) WO2017053556A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201890782A1 (ru) * 2015-09-22 2018-09-28 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ перенацеливания t-клеток для лечения инфекции hiv
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
SI3443006T1 (sl) 2016-04-13 2024-01-31 Sanofi Trispecifični in/ali trivalentni vezni proteini
BR112018070998A2 (pt) 2016-04-13 2019-02-26 Sanofi proteínas de ligação triespecíficas e/ou trivalentes
WO2018208606A1 (en) * 2017-05-08 2018-11-15 The Regents Of The University Of California Protective chimeric antigen receptor stem cell gene therapy for viral infection
US20230070158A1 (en) * 2017-10-23 2023-03-09 City Of Hope CAR for Treatment of HIV Infection
CN108059675B (zh) * 2017-12-12 2021-09-10 武汉波睿达生物科技有限公司 重组pg9-car分子的构建及其在清除hiv-1感染细胞中的应用
JP7447388B2 (ja) * 2018-07-13 2024-03-12 ナンジン レジェンド バイオテック カンパニー，リミテッド 感染性疾患の治療のための共受容体システム
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
CN110358793A (zh) * 2019-05-30 2019-10-22 南京艾德免疫治疗研究院有限公司 一种用于car-t制备的慢病毒载体制备方法
CN110343175B (zh) * 2019-06-26 2021-02-26 深圳市再生之城生物医药技术有限公司 抑制HIV-1病毒感染的scFv序列及其应用
CA3170630A1 (en) * 2020-03-03 2021-09-10 American Gene Technologies International Inc. On demand expression of exogenous factors in lymphocytes to treat hiv
CN116917313A (zh) * 2021-12-31 2023-10-20 北京三诺佳邑生物技术有限责任公司 靶向hiv感染细胞的嵌合抗原受体t细胞

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
WO1993006216A1 (en) * 1991-09-26 1993-04-01 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CZ293943B6 (cs) * 1994-08-02 2004-08-18 Theágeneraláhospitalácorporation Způsob výroby buňkyŹ která exprimuje membránově vázaný bílkovinný chimerní receptorŹ příbuzné molekuly a materiály
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
MX347078B (es) * 2010-12-09 2017-04-10 Univ Pennsylvania Uso de celulas t modificadas por receptor de antigeno quimerico para tratar cancer.
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
MX370495B (es) * 2012-07-13 2019-12-13 Univ Pennsylvania Métodos para evaluar la conveniencia de células t transducidas para administración.
TW201446794A (zh) * 2013-02-20 2014-12-16 Novartis Ag 利用抗－ｃｄ１２３嵌合抗原受體工程化ｔ細胞之初級人類白血病有效靶向
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP6516740B2 (ja) 2013-08-02 2019-05-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞及びキメラ抗原受容体を介した抗腫瘍性ｔ細胞免疫の改変
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
WO2015077789A2 (en) 2013-11-25 2015-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control hiv infection
CN111849912B (zh) * 2014-02-14 2024-03-15 贝里坤制药股份有限公司 用诱导型嵌合多肽活化t细胞的方法
CA2984484C (en) * 2014-05-02 2024-01-23 The Trustees Of The University Of Pennsylvania Compositions and methods of chimeric autoantibody receptor t cells
EA201890782A1 (ru) * 2015-09-22 2018-09-28 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Способ перенацеливания t-клеток для лечения инфекции hiv

Also Published As

Publication number Publication date
AU2016326500A1 (en) 2018-04-12
US20180265565A1 (en) 2018-09-20
MX2018003463A (es) 2018-09-06
EP3353197A4 (en) 2018-11-14
MA42951A (fr) 2018-08-01
US10738099B2 (en) 2020-08-11
CN108779161A (zh) 2018-11-09
JP2018527014A (ja) 2018-09-20
WO2017053556A1 (en) 2017-03-30
KR20180050413A (ko) 2018-05-14
EA201890782A1 (ru) 2018-09-28
EP3353197A1 (en) 2018-08-01
US20200362012A1 (en) 2020-11-19
IL258191A (en) 2018-05-31
JP6991131B2 (ja) 2022-02-03
CL2018000750A1 (es) 2018-12-28
PH12018500609A1 (en) 2018-10-01
CA2999496A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
BR112018005741A2 (pt) método de redirecionamento de células t para tratar infecção por hiv
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
CL2017001920A1 (es) Anticuerpos humanos contra glicoproteína del virus ébola
SV2018005634A (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
CL2018001971A1 (es) Ror1 composiciones de anticuerpos y métodos relacionados
UY36458A (es) Anticuerpos humanos para hemaglutinina influenza.
BR112019006106A2 (pt) formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio.
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
WO2016029073A3 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
BR112017001242A2 (pt) tratamento de câncer usando um receptor antigênico quimérico a cd33
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
MX2020003619A (es) Dosificacion y administracion de los anticuerpos anti-c5 para el tratamiento de los pacientes con glomerulonefritis membranoproliferativa.
BR112016027881A2 (pt) antagonistas de pdl-1 e pd-1 para o tratamento de cânceres negativos para o hpv
BR112019005685A2 (pt) células t com resistência à imunossupressão aumentada
BR112019002734A2 (pt) tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart
MX2014013678A (es) Agentes para neutralizacion de influenza.
BR112022003956A2 (pt) Anticorpos anti-cd73
BR112018013256A2 (pt) anticorpo para pcsk9, fragmento de ligação a antí-geno do mesmo e aplicação médica do mesmo
BR112017003252A2 (pt) terapia com anticorpos contra hiv como substituto de tratamento
BR112017009504A2 (pt) métodos para tratar e para curar uma infecção por hcv, e, composição farmacêutica.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]